Christina Yau

ORCID: 0000-0002-1937-0859

Also affiliated with University of San Francisco

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

60.1Author DataRank

Indexed papers

10in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 10 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Comprehensive genomic characterization of squamous cell lung cancers

Nature(2012)10.1038/nature11404

Top 1%

11.0DataRank

Top 1%4036 citations

Gad Getz, Stephen E. Schumacher, Petar Stojanov, Chang‐Jiun Wu, Hailei Zhang +326 more

Papers

Driven by 75 papers — median percentile 97. Top paper: “Comprehensive genomic characterization of squamous cell lung cancers”.

Comprehensive genomic characterization of squamous cell lung cancers

Nature(2012)10.1038/nature11404

Top 1%

11.0DataRank

Top 1%4036 citations

Gad Getz, Stephen E. Schumacher, Petar Stojanov, Chang‐Jiun Wu, Hailei Zhang +326 more

A global reference for human genetic variation

Nature(2015)10.1038/nature15393

Top 1%

10.6DataRank

Top 1%20166 citations

Gonçalo R. Abecasis, Richard M. Durbin, Panagiotis Deloukas, Aravinda Chakravarti, Peter Donnelly +516 more

Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel

Nature Communications(2014)10.1038/ncomms4934

Top 2%

8.3DataRank

Top 2%460 citations

Jonathan Marchini, Peter Donnelly, Gerton Lunter, Jonathan L. Marchini, Simon Myers +364 more

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell(2018)10.1016/j.cell.2018.02.052

Top 2%

8.1DataRank

Top 2%3980 citations

Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich +866 more

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

Cell(2018)10.1016/j.cell.2018.03.033

Top 3%

6.4DataRank

Top 3%447 citations

Matthew H. Bailey, Hoifung Poon, Vesteinn Thorsson, Antonio Colaprico, Andreas Bender +883 more

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Pan-cancer analysis of whole genomes

Nature(2020)10.1038/s41586-020-1969-6

Top 3%

5.9DataRank

Top 3%3307 citations

Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse, Hiroyuki Aburatani, David J. Adams +1244 more

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

Cell Reports(2018)10.1016/j.celrep.2018.03.046

N/A

5.5DataRank · unranked

186 citations

Francisco Sanchez-Vega, Konnor C. La, Joshua Armenia, Walid K. Chatila, Augustin Luna +869 more

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

Nature(2020)10.1038/s41586-020-1965-x

Top 5%

4.6DataRank

Top 5%668 citations

Federico Abascal, Jeremiah A. Wala, Ofer Shapira, Grace Tiao, Henrik Hornshøj +1240 more

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types

Nature Communications(2019)10.1038/s41467-019-11415-2

N/A

4.4DataRank · unranked

165 citations

BIN CHEN, Dvir Aran, J. Charalel, L. J. van ‘t Veer, Atul Janardhan Butte +6 more

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Nature Communications(2022)10.1038/s41467-022-31238-y

N/A

1.9DataRank · unranked

78 citations

Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila +18 more

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival

medRxiv(2020)10.1101/2020.02.03.20019760

N/A

1.6DataRank · unranked

41 citations

Lamorna Brown Swigart, Hsin-Ta Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +18 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Integrated genomic analyses of ovarian carcinoma

Nature(2011)10.1038/nature10166

N/A

1.3DataRank · unranked

8094 citations

Debra Bell, Andrew Berchuck, Michael J. Birrer, Jeremy Chien, D. W. Cramer +268 more

Oncogenic Signaling Pathways in The Cancer Genome Atlas

Cell(2018)10.1016/j.cell.2018.03.035

N/A

1.2DataRank · unranked

3322 citations

Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna, Konnor C. La +891 more

Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway

Cell Reports(2021)10.1016/j.celrep.2021.108707

N/A

1.1DataRank · unranked

32 citations

Xiaotong Yao, Siddhartha Devarakonda, Aditya Deshpande, Jeffrey S. Damrauer, Tiago C. Silva +77 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1

N/A

0.917DataRank · unranked

451 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

Annals of Oncology(2020)10.1016/j.annonc.2020.11.007

N/A

0.917DataRank · unranked

450 citations

Lamorna Brown Swigart, H.-T. Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +19 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0.873DataRank · unranked

337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets

Cancer Cell(2025)10.1016/j.ccell.2024.12.002

N/A

0.803DataRank · unranked

29 citations

Christopher K. Wong, Christina Yau, Mauro A.A. Castro, Jordan Lee, Brian Karlberg +24 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0.777DataRank · unranked

177 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL

npj Breast Cancer(2020)10.1038/s41523-020-00203-7

N/A

0.666DataRank · unranked

84 citations

David C. Newitt, Jessica Gibbs, Lisa J. Wilmes, Ella F. Jones, Vignesh A. Arasu +57 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0.648DataRank · unranked

74 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk

npj Breast Cancer(2021)10.1038/s41523-021-00239-3

N/A

0.598DataRank · unranked

53 citations

Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown Swigart +12 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011

N/A

0.574DataRank · unranked

45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response

Radiology(2021)10.1148/radiol.2021203645

N/A

0.550DataRank · unranked

38 citations

Wen Li, David C. Newitt, Roy Harnish, Fredrik Strand, Alex Nguyen +56 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0.510DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Annals of Oncology(2024)10.1016/j.annonc.2024.10.018

N/A

0.494DataRank · unranked

26 citations

David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs +15 more

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy

JAMA Network Open(2021)10.1001/jamanetworkopen.2021.14904

N/A

0.483DataRank · unranked

24 citations

Annelie Johansson, Anna Nordenskjöld, Adina Iftimi, Christina Yau, Gizeh Pérez‐Tenorio +7 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0.457DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

International Journal of Cancer(2022)10.1002/ijc.33969

N/A

0.449DataRank · unranked

19 citations

Nancy Yu, Adina Iftimi, Nicholas P. Tobin, Laura van 't Veer, Bo Nordenskjöld +8 more

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101312

N/A

0.442DataRank · unranked

18 citations

Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina Yau, Nicholas O’Grady +22 more

Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas

UNC Libraries(2020)10.17615/jcyr-9v75

N/A

0.442DataRank · unranked

18 citations

Candace Shelton, Matthew Meyerson, Carrie Cibulskis, Jia Liu, Joshua Armenia +95 more

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06914-2

N/A

0.441DataRank · unranked

7 citations

Rebecca Shatsky, Richard B. Schwab, Anne M. Wallace, Denise M. Wolf, Gillian L. Hirst +7 more

S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models

Communications Medicine(2024)10.1038/s43856-024-00444-8

N/A

0.424DataRank · unranked

8 citations

Adrienne Orriols, Μαρκέλλα Ζαννίκου, Chen Yeh, Pranathi Vadlamani, Deepak Kanojia +12 more

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.504

N/A

0.416DataRank · unranked

15 citations

Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, A. Jo Chien, Christina Yau +7 more

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2928

N/A

0.406DataRank · unranked

14 citations

Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau +13 more

Analytical protocol to identify local ancestry-associated molecular features in cancer

STAR Protocols(2021)10.1016/j.xpro.2021.100766

N/A

0.400DataRank · unranked

9 citations

Seunghun Han, Liangtao Zheng, Jeffrey S. Damrauer, Anab Kemal, Ashton C. Berger +35 more

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae268

N/A

0.394DataRank · unranked

5 citations

Huma Dar, Anna Nordenskjöld, Gizeh Pérez‐Tenorio, Nicholas P. Tobin, Christina Yau +8 more

Development and testing of a polygenic risk score for breast cancer aggressiveness

npj Precision Oncology(2023)10.1038/s41698-023-00382-z

N/A

0.373DataRank · unranked

11 citations

Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart +18 more

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

JAMIA Open(2021)10.1093/jamiaopen/ooab038

Top 51%

0.346DataRank

Top 51%2 citations

David L. Gibbs, Kawther Abdilleh, Adam L. Asare, Smita Asare, Sara J. Venters +8 more

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101799

N/A

0.345DataRank · unranked

9 citations

Denise M. Wolf, Christina Yau, Lamorna Brown Swigart, Julie Wulfkuhle, Isela Gallagher +21 more

MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer

Tomography(2025)10.3390/tomography11030026

N/A

0.300DataRank · unranked

4 citations

Natsuko Onishi, Jessica Gibbs, Lisa J. Wilmes, Nu N. Le, Pouya Metanat +12 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

Frontiers in Oncology(2023)10.3389/fonc.2023.1192208

N/A

0.297DataRank · unranked

5 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +10 more

Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.591

N/A

0.292DataRank · unranked

6 citations

Rebecca Shatsky, Christina Yau, Denise M. Wolf, Rita Nanda, L. J. van ‘t Veer +4 more

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

Nature Communications(2025)10.1038/s41467-025-65432-5

N/A

0.292DataRank · unranked

6 citations

Nayelis A. Manon, Denise M. Wolf, Samuel Rivero-Hinojosa, Ziad Ahmed, Rosalyn W. Sayaman +20 more

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07555-9

N/A

0.255DataRank · unranked

4 citations

Mike Campbell, Christina Yau, A. Jo Chien, Anne M. Wallace, Claudine Isaacs +18 more

Combinatorial Immunotherapies Overcome MYC-Driven Immune Evasion

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.05.07.442684

N/A

0.241DataRank · unranked

4 citations

Filomena Housley, Christina Yau, Daniel Van de Mark, Rachel Nakagawa, Golzar Hemmati +11 more

Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events

npj Breast Cancer(2025)10.1038/s41523-025-00774-3

N/A

0.208DataRank · unranked

3 citations

Christina Yau, Emma Iaconetti, Eliza Jeong, Case Brabham, Paul Kim +7 more

Tumor microenvironmental determinants of high-risk DCIS progression

Research Square(2024)10.21203/rs.3.rs-4126092/v1

N/A

0.182DataRank · unranked

2 citations

Alexa Glencer, Kirithiga Ramalingam, Nicole Schindler, Hidetoshi Mori, Parchi Ghule +13 more

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba612

N/A

0.165DataRank · unranked

2 citations

Alexandra Thomas, Christina Yau, A. Jo Chien, Carla I. Falkson, Erica Stringer-Reasor +15 more

Author Correction: Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

Communications Biology(2022)10.1038/s42003-022-03769-z

N/A

0.165DataRank · unranked

2 citations

Lars Feuerbach, Chen Hong, David Mas-Ponte, Randi Istrup Pedersen, PCAWG Drivers and Functional Interpretation Group +1255 more

Analysis of germline-driven ancestry-associated gene expression in cancers

STAR Protocols(2022)10.1016/j.xpro.2022.101586

N/A

0.165DataRank · unranked

2 citations

Rosalyn W. Sayaman, Donglei Hu, Scott Huntsman, Ashton C. Berger, Seunghun Han +37 more

Development and testing of a polygenic risk score for breast cancer aggressiveness

medRxiv(2022)10.1101/2022.08.26.22278957

N/A

0.165DataRank · unranked

2 citations

Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart +18 more

Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

Annals of Surgical Oncology(2025)10.1245/s10434-025-17864-y

N/A

0.104DataRank · unranked

1 citations

Katrina Dimitroff, Judy C. Boughey, Laura J. Esserman, Christina Yau, Julia Tchou +34 more

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.514

N/A

0.104DataRank · unranked

1 citations

Denise M. Wolf, Christina Yau, Emanuel F. Petricoin, Paula R. Pohlmann, Lajos Pusztai +10 more

Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.510

N/A

0.104DataRank · unranked

1 citations

Amy S. Clark, Christina Yau, Denise M. Wolf, L. J. van ‘t Veer, Emily Douglas +10 more

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.592

N/A

0.104DataRank · unranked

1 citations

Paige Warner, Robert Hiatt, Scarlett Lin Gomez, L. J. van ‘t Veer, Allison Stover Fiscalini +11 more

Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ

npj Breast Cancer(2024)10.1038/s41523-024-00677-9

N/A

0DataRank · unranked

3 citations

Cristian K. Maldonado Rodas, Rita I. Freimanis, Alexa Glencer, Phoebe Miller, Rita A. Mukhtar +10 more

Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial

Breast Cancer Research and Treatment(2024)10.1007/s10549-023-07214-5

N/A

0DataRank · unranked

5 citations

Douglas Yee, David A. Potter, Patricia Jewett, Christina Yau, Heather Beckwith +7 more

Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers

Research Square(2024)10.21203/rs.3.rs-3403438/v1

N/A

0DataRank · unranked

1 citations

Christina Yau, Emma Iaconetti, Eliza Jeong, Case Brabham, Paul Kim +7 more

Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower

Nature Communications(2022)10.1038/s41467-022-32343-8

N/A

0DataRank · unranked

0 citations

PCAWG Drivers and Functional Interpretation Working Group, Federico Abascal, Samirkumar B. Amin, Pratiti Bandopadhayay, Rameen Beroukhim +1242 more

Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets

UNC Libraries(2025)10.17615/jwhb-3p36

N/A

0DataRank · unranked

0 citations

Anab Kemal, Mauro A.A. Castro, Christina Yau, Andrew D. Cherniack, Ina Felau +25 more

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba520

N/A

0DataRank · unranked

2 citations

Kevin Kalinsky, Christina Yau, A. Jo Chien, Judy C. Boughey, Erica Stringer-Reasor +15 more

356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study

Annals of Oncology(2023)10.1016/j.annonc.2023.09.535

N/A

0DataRank · unranked

1 citations

Helena Earl, Christina Yau, David Cameron, Jean Abraham, Larry Hayward +15 more

Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial

Research Square(2023)10.21203/rs.3.rs-2588168/v1

N/A

0DataRank · unranked

0 citations

Douglas Yee, David A. Potter, Patricia Jewett, Christina Yau, Heather Beckwith +7 more

355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.534

N/A

0DataRank · unranked

2 citations

Elizabeth Price, Sara J. Venters, Wěi Li, Denise M. Wolf, Jessica Gibbs +14 more

Protocol for obtaining cancer type and subtype predictions using subSCOPE

STAR Protocols(2025)10.1016/j.xpro.2025.103705

N/A

0DataRank · unranked

0 citations

A. Gordon Robertson, Kyle Ellrott, Christopher K. Wong, Jordan Lee, Christina Yau +54 more

Protocol for assessing distances in pathway space for classifier feature sets from machine learning methods

STAR Protocols(2025)10.1016/j.xpro.2025.103681

N/A

0DataRank · unranked

0 citations

Victor H Apolonio, Vinicius S Chagas, Christopher K. Wong, Jordan Lee, Christina Yau +61 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.30.534178

N/A

0DataRank · unranked

0 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +11 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

S100A8/A9 predicts triple-negative breast cancer response to PIM kinase and PD-1/PD-L1 inhibition

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.09.21.558870

N/A

0DataRank · unranked

1 citations

Adrienne Orriols, Μαρκέλλα Ζαννίκου, Chen Yeh, Pranathi Vadlamani, Deepak Kanojia +12 more

Christina Yau

Indexed papers

Top data-sharing exemplar

Papers